PepGen Inc. (PEPG)
NASDAQ: PEPG · Real-Time Price · USD
1.415
-0.065 (-4.39%)
Mar 31, 2025, 1:25 PM EDT - Market open
PepGen Employees
PepGen had 81 employees as of December 31, 2024. The number of employees increased by 17 or 26.56% compared to the previous year.
Employees
81
Change (1Y)
17
Growth (1Y)
26.56%
Revenue / Employee
n/a
Profits / Employee
-$1,110,877
Market Cap
46.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Dec 31, 2023 | 64 | 19 | 42.22% |
| Dec 31, 2022 | 45 | 14 | 45.16% |
| Dec 31, 2021 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PEPG News
- 20 days ago - PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference - Business Wire
- 26 days ago - PepGen To Voluntarily Pause Mid-Stage Duchenne Muscular Dystrophy Study, Stock Falls - Benzinga
- 27 days ago - PepGen to Participate in Upcoming Investor Conferences - Business Wire
- 27 days ago - PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD - Business Wire
- 5 weeks ago - PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights - Business Wire
- 5 weeks ago - PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 - Business Wire
- 2 months ago - PepGen Announces CONNECT Program Updates - Business Wire
- 3 months ago - PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy - Business Wire